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Abstract  
Purpose of review: Malignant pleural mesothelioma is an aggressive malignancy with a very poor 
prognosis. The majority of patients require pleural procedures for diagnostic or fluid management 
purposes. Damage to the pleura during these procedures can lead to procedure tract metastases 
(PTMs), with increasing risk from larger interventions. Prophylactic radiotherapy to these sites is a 
controversial topic with conflicting results from trial data. In this review we summarise the recent 
evidence.  
Recent findings: Four RCTs have been published on this topic, with another in follow-up. The earliest, 
from a cohort of 40 patients, strongly advocated the use of prophylactic radiotherapy. More recent 
trials, most notably the SMART trial (which randomised over 200 patients) did not demonstrate any 
benefit, especially when patient report symptoms and cost-effectiveness are considered. Certain 
subgroups demand further investigation, such as those not receiving systematic chemotherapy or 
with surgical intervention sites. The soon to be published PIT trial may help to further clarify best 
practice.  
Summary: Recent studies have shown that prophylactic radiotherapy should not be routinely used to 
prevent PTMs in mesothelioma. Instead patients should undergo careful clinical follow up to ensure 
PTMs are identified and treated promptly to minimise symptoms.   
Keywords; mesothelioma, prophylactic, radiotherapy, metastasis  
 
Introduction 
Malignant pleural mesothelioma (MPM) is an aggressive and invariably fatal malignancy. Average 
survival is 9-14 months from diagnosis and patients often experience disabling symptoms of pain 
and breathlessness [1]. Patients with mesothelioma usually require pleural interventions for tissue 
diagnosis and fluid management. Prophylactic radiotherapy to intervention sites has previously been 
recommended to reduce the occurrence of procedure-tract metastases (PTMs). There has been 
significant equipoise about the efficacy of prophylactic radiotherapy, reflected in conflicting 
recommendations from international guidelines. The aim of this review was to summarise the recent 
literature surrounding this topic.  
 
Procedure Tract Metastases 
The diagnosis of MPM can be challenging. On computerised tomography (CT) scans the tumour can 
mimic other causes of both malignant and benign pleural thickening. The diagnostic yield from 
pleural fluid cytology  in mesothelioma is notoriously low [2]. Resultantly, patients usually require a 
CT guided biopsy, thoracoscopy or Video Assisted Thorascopic Surgery (VATS) in order to obtain 
tissue for histological confirmation of the diagnosis. Furthermore, once a diagnosis of MPM is made, 
patients may experience troubling breathlessness due to the re-accumulation of pleural fluid, 
necessitating therapeutic pleural aspirations, chest drain or indwelling pleural catheter (IPC) 
insertion to manage their symptoms.  
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A complication of instrumentation of the pleura in MPM is seeding of malignant cells along the 
procedural tract, which can result in the development of PTMs. These subcutaneous nodules (see 
Figure 1), may develop many months after the initial procedure and can be painful. It is not clear 
whether they develop due to deposition of pleural fluid containing tumour cells into the 
subcutaneous tissues during the pleural procedure or whether disruption to the tumour on the 
pleural surface during the intervention stimulates the tumour to grow along the procedure tract (2).  
The incidence of PTM in patients with MPM varies widely and is likely due to a number of factors. A 
retrospective case series published by Agarwal et al demonstrated that the risk of PTM development 
was related to the size of chest wall incision. The incidence of PTM after small bore procedures was 
minimal (3.6 % of patients developed a PTM after thoracentesis) but increased with more invasive 
procedures (16% following thoracoscopy and 24% after a thoracotomy) [3]. It is probable that other 
procedural, host and tumour factors also contribute an individual’s risk of a PTM developing, which 
may explain the disparity in the incidence of PTMs in the literature.  
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Figure 1; Patient with a large painless procedure tract metastasis and indwelling pleural catheter.  
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In vitro studies have demonstrated that mesothelioma tumour cells are highly radiosensitive [4]. In 
spite of this, the large treatment volumes and substantial toxicity to other thoracic organs required 
for radical treatment of MPM precludes its use for this purpose [5]. However, prophylactic 
radiotherapy to the tracts of previous thoracic interventions to prevent subsequent development of 
PTM is feasible but conflicting results from three small RCTs and a number of case series evaluating 
its efficacy has resulted in a long running debate about its efficacy (Table 1).  This clinical equipoise is 
reflected in substantial variation in clinical practice guidance from different organisations around the 
world (see Table 2).  
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Table 1. Summary of literature 
 
Author, year Study Type Number of 
patients 
Pleural 
procedure 
type 
Radiotherapy regimen 
- max time from 
procedure to RT 
- Dose and fractionation 
- Energy 
- Field size 
PTMs in 
controls 
PTMs in 
intervention 
group 
Odds ratio 
[95% CI] 
(p-value) 
Randomised 
controlled trials 
       
Boutin, 
1995 [6] 
RCT 40 LAT- 40 15 days 
21Gy in 3 fractions 
12.5 to 15 MeV 
16 to 100cm2  
8/20 
(40%) 
0/20 
(0%) 
0.04* 
[0.01-0.70] 
p<0.01 
Bydder, 
2004 [7] 
RCT 43 
(58 sites) 
CD/LAT- 22 
FNA- 27 
Abrams- 9 
15 days 
10Gy in 1 dose 
9 MeV 
ND 
3/30 
(10%) 
2/28 
(7%) 
0.70* 
[0.11-4.49] 
p= 0.53 
O’Rourke, 
2007 [8] 
RCT 61 CD-15 
PB- 27 
LAT- 16 
Un- 3 
21 days 
21 Gy in 3 fractions 
9-12 MeV 
6 cm diameter circle 
3/30 
(10%) 
4/31 
(13%) 
1.33* 
[0.27-6.53] 
p=0.75 
Clive,  
2016 [9] 
RCT 203 Wide CD- 3 
LAT- 74 
Thor- 9 
VATS- 91 
IPC- 25 
CGB- 1 
42 days 
21 Gy in 3 fractions 
Variable 
>7 cm diameter  
 
16/101 
(16%) 
9/102 
(9%) 
0.51 
[0.19-1.32] 
p= 0.14 
Bayman, 
2016 [10] 
RCT 374 Awaited 42 days 
21 Gy in 3 fractions 
Single electron field 
Trial led 
Awaited Awaited Awaited 
Case series and 
cohort studies 
       
Low, 
1995 [11] 
Retrospective 
case series  
20 
(from 38 
intervention 
sites) 
ND 15 days 
21 Gy in 3 fractions 
140 or 250 KV 
4cm diameter 
n/a 0/38 
(0%) 
n/a 
Cellerin, 
2004 [12] 
Retrospective 
cohort study 
58 ND Variable 12/25 
(48%) 
7/33 
(21%) 
0.29* 
[0.09-0.92] 
p=0.04 
West, 
2006 [13] 
Retrospective 
case series 
37 
 
ND ND 
21 Gy in 3 fractions 
10 MeV 
Variable 
n/a 2/37 
(5%) 
n/a 
Di Salvo, 
2008 [14] 
Retrospective 
case series 
32 FNA- 21 
TCentesis- 5 
LAT- 5 
PD- 1 
Variable 
21 Gy in 3 fractions 
12 MeV 
100 cm2 
n/a 0/32 
(0%) 
n/a 
Metintas,  
2008 [15] 
 
Retrospective 
case series 
212 CGB/PB- 135 
LAT- 46 
Thor- 31 
n/a 28/212 
(13%) 
n/a n/a 
Kara, 
2010 [16] 
Retrospective 
case series 
19 PB- 8 
LAT- 6 
Thor- 3 
VATS- 8 
PD/EPP- 7 
27 days 
21 Gy in 3 fractions 
12 MeV 
Variable 
n/a 0/19 
(0%) 
n/a 
Froment, 
2011 [17] 
Retrospective 
cohort study 
171 ND 36 days 
Various radiotherapy 
regimens 
40/123 
(33%) 
6/48 
(13%) 
0.27* 
[0.12-0.76] 
P<0.01 
Akmansu, 
2013 [18] 
Retrospective 
case series 
27 ND 69 days 
Variable 
4-15 MeV 
Variable 
3/27 
(12%) 
n/a n/a 
Janssen,  
2015 [19] 
 
Retrospective 
case series 
52 VATS- 53 40 days 
21 Gy in 3 fractions 
6-18 MeV 
Variable  
3/53 
(6%) 
n/a n/a 
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Table abbreviations; RCT- Randomised controlled trial, LAT- Local anaesthetic thoracoscopy, CD- Chest drain, FNA- Fine needle aspiration, 
TCentesis- Thoracocentesis, PB- Pleural biopsy, PD- Pleural decortication, EPP- Extrapleural pneumonectomy, Thor- Thoracotomy, VATS- 
Video assisted thoracoscopic surgery, IPC- Indwelling pleural catheter, CGB- CT guided biopsy, Gy= Gray, MeV=ND- Not documented, Un- 
Unknown, *- Odds Ratio not reported in primary paper but calculated from reported data.   
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Table 2: Recommendations regarding prophylactic irradiation of tracts from the current mesothelioma clinical 
practice guidelines 
Guideline Year Prophylactic RT 
recommended? 
Recommendation regarding prophylactic RT 
British Thoracic Society Consensus 
Statement [20] 
2007 Yes ‘If good performance score and after more 
invasive procedures’ 
European Respiratory Society [21] 2010 No recommendation ‘value of prophylactic radiotherapy is 
questionable’ 
National Comprehensive Cancer 
Network (NCCN) [22] 
2016 Yes ’21 Gray in 3 fractions to surgical sites’ 
Journal of Thoracic Diseases [23] 2013 No ‘Prophylactic radiotherapy… has no 
significant effect on changing the disease 
course’ 
European Society for Medical Oncology 
(ESMO) [24] 
2015 Not unless part of a 
clinical trial 
‘probably best to recommend refraining 
from this procedure unless in the setting of a 
clinical trial’ 
Spanish Society of Medical Oncology 
(SEOM)  
2011 No ‘no sufficient evidence to definitively 
recommend it’ 
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Effect of prophylactic radiotherapy on PTM incidence 
The first randomised controlled trial (RCT) investigating the role of prophylactic radiotherapy in 
preventing PTMs in MPM was performed by Boutin et al in 1995 [6]. Forty patients were randomised 
to either receive 21 Gray in three fractions over 3 days to their thoracoscopy site, very soon (10-15 
days) after thoracoscopy, or no radiotherapy. No PTMs were identified in the intervention group 
(0/20) compared to 8/20 (40%) in the control group, which led them to conclude that radiotherapy 
was not only safe but extremely effective in preventing PTMs. A retrospective case series published 
the same year appeared to support their findings (0 % vs 21 % PTM incidence in radiotherapy and 
non-radiotherapy groups) [11].  
However, clinical equipoise remained, as the very high PTM incidence in the control arm of Boutin’s 
study was not felt to reflect that seen by clinicians in everyday clinical practice.  This led to the 
publication of an RCT [7] from Australia, which showed no significant difference in PTM incidence 
between the treatment and control arms. However, the radiotherapy regimen of a single 10 Gray 
dose was much lower than the 21 Gray used in the previous study and the overall PTM incidence in 
the trial was lower, probably because patients who had undergone small bore interventions (which 
are lower risk for PTM development) were included. In view of this and despite the negative finding 
of the trial, the authors continued to advocate the use of 21 Gray in 3 fractions of prophylactic 
radiotherapy for high risk pleural interventions to prevent PTMs.  
Given the ongoing controversy, a further RCT was conducted in the UK by O'Rourke in 2007 [8]. This 
study randomised 61 patients with MPM who had undergone a recent pleural intervention to 
receive 21 Gray in 3 fractions within 21 days or no prophylactic radiotherapy. The inclusion of 
patients following small bore pleural procedures explains the lower overall incidence of PTMs (7/61) 
but not the lack of treatment effect of 13% versus 10% between the treatment and control arms 
respectively. The authors concluded that local radiotherapy should only be used after the 
development of a symptomatic PTM and not as prophylaxis.  
Three systematic reviews of the literature have been performed, which included the above RCTs [5, 
25, 26]. Although the RCTs are heterogeneous in terms of study design and radiotherapy regimens, 
when the data was pooled, no difference between treatment and control arms was demonstrated.  
Since the publication of these trials there has been a shift in the management of MPM. Firstly, the 
majority of eligible patients are now offered palliative pemetrexed-based chemotherapy [27]. In 
addition, indwelling pleural catheters (IPCs) are increasingly used for pleural fluid management as 
opposed to standard chest drain with pleurodesis. The continuing equipoise around the efficacy of 
prophylactic radiotherapy, and the uncertainty regarding the potential impact of chemotherapy and 
IPCs on its efficacy, led to a desire from the mesothelioma community for further randomised data 
to clarify the situation further [25].  
The recently published SMART trial aimed to reassess the role of prophylactic radiotherapy in 
modern MPM management and included more extensive symptom control, health related quality of 
life (HRQoL) and health economic assessment than the previous studies [9]. This UK based multi-
centre RCT randomised patients to 'immediate' radiotherapy, within 42 days, or 'deferred' 
radiotherapy, where radiotherapy was performed only if PTMs developed. In order to account for 
the low incidence of PTMs seen in previous studies, the inclusion criteria involved only ‘large-bore’ 
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procedures (thoracoscopy, VATS, thoracotomy and, for the first time, indwelling pleural catheters). 
Twenty-one Gray in 3 fractions of radiotherapy was delivered and the field selected based on visible 
intervention sites with at least a 3cm margin and a minimum diameter of 7cm. Two hundred and 
three patients were randomised across 22 centres. The primary, intention to treat analysis after 12 
months of follow up revealed no significant difference in the incidence of PTMs between the 
'immediate' (9/102) and 'deferred' (16/101) groups (odds ratio (OR) 0·51 (0.19-0.32); p=0·14).  
However, there were 11 protocol violations relating to radiotherapy delivery in the immediate 
radiotherapy group and the pre-defined per-protocol analysis demonstrated a marginally significant 
difference in PTM incidence between the treatment groups in favour of immediate radiotherapy (OR 
0.33 (0.09-1.00) p= 0.04).  This highlights that if prophylactic radiotherapy is to be delivered, 
accurate and timely administration is paramount.  However, whether this is feasible for all-comers 
outside the context of a clinical trial is questionable.  This, along with the lack of symptom or quality 
of life benefit (see later) led the SMART trial authors to conclude that routine use of prophylactic 
radiotherapy in all patients with MPM after a large bore intervention was not beneficial. 
Effect of prophylactic radiotherapy on symptoms and quality of life  
It is vital when considering the efficacy of prophylactic radiotherapy to consider the effect of the 
treatment and PTMs on the patient’s symptoms and quality of life.  Treatment of mesothelioma is 
palliative and the rigorous follow up of randomised trials may result in the detection of small, 
asymptomatic nodules which are not of clinical consequence to the individual.  Hence the evaluation 
of patient centred secondary endpoints in conjunction with the incidence of chest wall nodules is 
critical. 
The first RCT to include any patient reported outcome data was the O’Rourke study. Condition-
specific questionnaires were completed by the 7 patients who developed PTMs of which three 
reported the PTM to be uncomfortable.  Patients also completed the ‘Hospital Anxiety and 
Depression’ questionnaire during their 12 month follow up, although only 39/61 patients had usable 
data.  They did identify significantly worse anxiety levels in the prophylactic radiotherapy group and 
worse depression in the control group although the small numbers in each analysis limits its 
interpretation.  
 
The SMART trial examined symptom control, analgesia use and health-related quality of life (HRQoL) 
across the entire cohort and found no significant differences in any of these patient centred 
outcomes between the treatment groups during 12 month follow up. In fact, only one-third of PTMs 
were painful at the time of identification and no significant differences were seen in the pain scores 
or analgesia use of patients who developed a PTM between the treatment groups during their 
remaining follow up. The radiotherapy was well tolerated and no complications from delivery of 
radiotherapy to IPCs were identified. 
 
Cost-effectiveness of prophylactic radiotherapy 
The SMART trial is the only trial to date to evaluate the health economic impact of delivering 
prophylactic radiotherapy in mesothelioma. The mean total costs and QALYs of the two arms were 
comparable, resulting in no significant difference in the point estimate of the incremental cost-
effectiveness ratio between the groups.  Based on this data, delivery of prophylactic radiotherapy 
was not deemed cost effective although full health economic assessment of the SMART trial data is 
awaited. 
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Areas warranting further investigation 
None of the published studies are sufficiently powered to conclusively evaluate whether 
prophylactic radiotherapy benefits specific subgroups of patients with MPM, however some 
potential signals were identified by the SMART trial, which may warrant further investigation. 
Although it did not reach statistical significance, the SMART trial showed a trend for patients with 
epithelioid-only features on histology to benefit from prophylactic radiotherapy in terms of PTM 
incidence (6/71 (8%) in the immediate radiotherapy developed a PTM compared with 15/72 (21%) in 
the deferred arm (OR 0.35 (0.11–1.04) p= 0.057)).  This is likely to be related to the improved 
survival and therefore duration of benefit in this group compared to those with other histological 
subtypes.  
Subgroup analysis of the SMART cohort also suggested that patients not receiving chemotherapy 
may benefit from prophylactic radiotherapy in terms of reducing PTM incidence (2/46 (4%) vs 8/37 
(22%) in the immediate and deferred radiotherapy groups respectively (p= 0.02)). This may reflect 
that systemic chemotherapy effectively targets residual tumour cells seeded at the site of previous 
pleural interventions, negating the need for prophylactic radiotherapy as well.  It may also explain 
why some of the older studies, conducted before the use of pemetrexed based treatment regimens 
appeared to show prophylactic radiotherapy to be more effective.   
The use of IPCs for fluid management of persistent pleural effusions has increased markedly since 
the early prophylactic radiotherapy studies. The SMART trial agreed with the non-randomised data 
suggesting delivering radiotherapy to these catheters was not associated with complications or 
device damage [28, 29].  However, the incidence of PTM was not reduced by delivering prophylactic 
radiotherapy to patients with IPCs, although the numbers were small.  
The cohorts recruited to the aforementioned RCTs have only included a small proportion of patients 
who have large thoracotomy scars from surgical procedures, with 9 in the SMART trial and none in 
the Boutin, Bydder and O’Rourke trials.  Agarwal et al retrospectively observed 5/21 patients who 
had a thoracotomy developed a PTM.   Given the lack of proven efficacy of radical surgical 
treatments for mesothelioma [30], only small numbers of patients are currently undergoing thoracic 
surgery [31].  It could be argued however, that these patients with the largest scars potentially have 
the most to benefit from prophylactic radiotherapy but the current studies have not recruited 
sufficient patients in this group to quantify its potential benefit. Should more invasive surgical 
interventions be established in the future, this may warrant reconsideration.   
Future trials 
It is hoped that The PIT Trial, another large, UK based RCT aimed at assessing the benefit of 
prophylactic radiotherapy in MPM which is currently in follow up will help clarify the ongoing 
uncertainties relating to its use in these subgroups [10, 32-35]. This trial has recruited 374 patients 
over two years and is currently in follow up.  It randomised patients to either 21 Gray in 3 fractions 
of prophylactic radiotherapy with a superiorly configured field to take into account skin movement 
around the scar or no radiotherapy. The primary endpoint is the occurrence of PTMs 6 months after 
randomisation but patients will be followed up for 2 years with regular telephone consultations. 
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Close liaison between the SMART and PIT trial teams has ensured the data from the 2 trials can be 
combined to allow for future meta-analysis.   
Conclusion 
The role of prophylactic irradiation of tracts in mesothelioma is a much debated subject area, with 
controversy about its efficacy spanning a number of decades.  Based on the body of randomised 
evidence, there is no evidence to suggest prophylactic irradiation of tracts is effective in reducing 
PTM incidence if delivered to all-comers with mesothelioma after pleural interventions.  Even if it 
were to be mildly efficacious if delivered quickly and accurately after a pleural intervention, the lack 
of any symptom or quality of life benefits from the SMART study, would suggest that in this would 
not confer any patient-centered benefit above careful clinical follow up.  These patients have a 
limited lifespan with only palliative treatments available to them and hence these patient-focused 
outcomes are of paramount importance.  
Further data is required to ascertain whether certain patient groups, such as those with epithelioid-
only histology or those not undergoing chemotherapy stand to benefit from prophylactic 
radiotherapy and it is hoped the PIT study data will clarify this further. 
Based on the available clinical trial data, we would not advocate the routine prophylactic irradiation 
of tracts in mesothelioma, but instead careful clinical follow up to ensure PTMs are identified and 
treated promptly to minimise symptoms. 
 
Key points 
• Prophylactic radiotherapy to prevent procedure tract metastases (PTMs) is a controversial 
topic with conflicting results from randomised controlled trials.  
• Recent larger trials have not shown any evidence that routine use of prophylactic 
radiotherapy reduces incidence of PTMs.  
• Certain subgroups of patients may benefit more from prophylactic radiotherapy, such as 
those with epithelioid disease not receiving systemic chemotherapy, and future studies may 
help to clarify best practice.   
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